Ligand Pharmaceuticals (LGND) Peer Comparison
$286.92
$2.65
(0.93%)
As on 02-Sep-2026 16:00EDT
Market cap
$5,592 Mln
Revenue (TTM)
$291 Mln
P/E Ratio
28.9
P/B Ratio
5.9
Div. Yield
0 %
Edit
| Ligand Pharmaceuticals (LGND) | BridgeBio Pharma (BBIO) | Corcept Therapeutics (CORT) | Elanco Animal Health (ELAN) | Axsome Therapeutics (AXSM) | |
|---|---|---|---|---|---|
Market cap ($ Mln) |
5,592 | 14,975 | 12,310 | 11,972 | 10,425 |
Revenue ($ Mln) |
291 | 692 | 831 | 5,020 | 777 |
Net Profit ($ Mln) |
197.22 | -696.24 | 54.90 | -199.00 | -191.64 |
Net Margin (%) |
67.88 | -100.64 | 6.61 | -3.96 | -24.68 |
RoE (%) |
19.87 | -- | 8.11 | -3.03 | -223.36 |
Price to Earnings |
28.92 | -- | 264.84 | -- | -- |
Price-To-Book |
5.86 | 123.68 | 17.91 | 1.79 | 129.60 |
Income Statement ($ Mln)
| Ligand Pharmaceuticals (LGND) | BridgeBio Pharma (BBIO) | Corcept Therapeutics (CORT) | Elanco Animal Health (ELAN) | Axsome Therapeutics (AXSM) | |
|---|---|---|---|---|---|
|
Operating Revenue
|
290.54 | 691.84 | 830.81 | 5,020.00 | 776.57 |
|
Cost of Revenue
|
4.12 | 47.45 | 14.09 | 2,380.00 | 52.53 |
|
Gross Profit
|
261.50 | 473.81 | 748.43 | 2,050.00 | 591.02 |
|
Operating Expenses
|
185.49 | 1,187.86 | 810.32 | 2,178.00 | 912.58 |
|
Operating Profit (EBIT)
|
100.93 | -543.47 | 6.41 | 462.00 | -188.54 |
|
Other Income
|
0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
|
Profit before Tax
|
237.96 | -706.17 | 26.37 | -166.00 | -191.09 |
|
Provision for Tax
|
40.74 | -7.73 | -35.26 | 33.00 | 0.56 |
|
Profit after Tax (Net Income)
|
197.22 | -696.24 | 54.90 | -199.00 | -191.64 |
|
Minority Interest
|
0.00 | 6.48 | 0.00 | 0.00 | 0.00 |
|
Consolidated Profit
|
0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Liabilities ($ Mln)
| Ligand Pharmaceuticals (LGND) | BridgeBio Pharma (BBIO) | Corcept Therapeutics (CORT) | Elanco Animal Health (ELAN) | Axsome Therapeutics (AXSM) | |
|---|---|---|---|---|---|
|
Shareholder's Funds
|
967.52 | -2,515.22 | 705.78 | 6,588.00 | 83.30 |
|
Minority Interest
|
0.00 | 6.48 | 0.00 | 0.00 | 0.00 |
|
Non-Current Liabilities
|
1,171.62 | 2,832.54 | 29.12 | 5,121.00 | 217.70 |
|
Current Liabilities
|
46.74 | 890.65 | 153.80 | 1,852.00 | 460.45 |
|
Total Liabilities
|
1,560.64 | 936.03 | 836.65 | 13,358.00 | 689.81 |
Assets ($ Mln)
| Ligand Pharmaceuticals (LGND) | BridgeBio Pharma (BBIO) | Corcept Therapeutics (CORT) | Elanco Animal Health (ELAN) | Axsome Therapeutics (AXSM) | |
|---|---|---|---|---|---|
|
Non-Current Assets
|
728.76 | 124.16 | 449.03 | 9,764.00 | 104.88 |
|
Current Assets
|
1,457.12 | 1,093.14 | 439.68 | 3,797.00 | 656.57 |
|
Total Assets
|
1,560.64 | 936.03 | 836.65 | 13,358.00 | 689.81 |
|
Total Debt*
|
1,131.45 | 2,493.78 | 9.42 | 3,918.00 | 219.21 |
|
Net Current Assets
|
1,410.38 | 0.00 | 285.87 | 1,945.00 | 0.00 |
Cashflow ($ Mln)
| Ligand Pharmaceuticals (LGND) | BridgeBio Pharma (BBIO) | Corcept Therapeutics (CORT) | Elanco Animal Health (ELAN) | Axsome Therapeutics (AXSM) | |
|---|---|---|---|---|---|
|
Cash From Operating Activities
|
49.36 | -445.91 | 142.00 | 560.00 | -93.41 |
|
Cash Flow from Investing Activities
|
-377.32 | -24.49 | 69.76 | -279.00 | -0.48 |
|
Cash from Financing Activities
|
428.22 | 359.29 | -220.37 | -275.00 | 101.47 |
|
Net Cash Inflow / Outflow
|
-- | -- | -- | -- | -- |
Ratios
Profitability Ratios
| Ligand Pharmaceuticals (LGND) | BridgeBio Pharma (BBIO) | Corcept Therapeutics (CORT) | Elanco Animal Health (ELAN) | Axsome Therapeutics (AXSM) | |
|---|---|---|---|---|---|
|
ROCE (%)
|
10.79 | -159.44 | 14.87 | -2.21 | -63.21 |
|
ROE (%)
|
19.87 | 41.15 | 8.11 | -3.03 | -223.36 |
|
ROA (%)
|
12.15 | -39.04 | 5.52 | -1.30 | -15.97 |
|
EBIT Margin (%)
|
82.50 | -89.09 | 3.17 | 1.61 | -17.57 |
|
Net Margin (%)
|
67.88 | -100.64 | 6.61 | -3.96 | -24.68 |
|
Cash Profit Margin (%)
|
0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Growth Ratios
| Ligand Pharmaceuticals (LGND) | BridgeBio Pharma (BBIO) | Corcept Therapeutics (CORT) | Elanco Animal Health (ELAN) | Axsome Therapeutics (AXSM) | |
|---|---|---|---|---|---|
|
Revenue Growth (%)
|
54.89 | 193.38 | 16.02 | 11.95 | 56.87 |
|
EBIT Growth (%)
|
396.48 | 5.05 | -79.11 | -90.61 | 42.45 |
|
Net Profit Growth (%)
|
359.97 | 10.33 | -58.66 | -145.85 | 22.38 |
|
EPS Growth (%)
|
337.28 | 12.58 | -62.44 | -146.42 | 25.75 |
|
Book Value Growth (%)
|
6.56 | -36.90 | 12.98 | -3.87 | 9.44 |
Valuation Ratios
| Ligand Pharmaceuticals (LGND) | BridgeBio Pharma (BBIO) | Corcept Therapeutics (CORT) | Elanco Animal Health (ELAN) | Axsome Therapeutics (AXSM) | |
|---|---|---|---|---|---|
|
Price / Earnings
|
32.11 | -20.69 | 41.86 | -48.47 | -50.48 |
|
Price / Book Value
|
3.93 | -7.27 | 6.44 | 1.72 | 104.73 |
|
Dividend Yield (%)
|
-- | -- | -- | -- | -- |
|
EV/EBITDA
|
19.27 | -25.60 | 55.67 | 21.77 | -54.53 |
|
Market Cap ($ Cr)
|
-- | -- | -- | -- | -- |
Solvency Ratios
| Ligand Pharmaceuticals (LGND) | BridgeBio Pharma (BBIO) | Corcept Therapeutics (CORT) | Elanco Animal Health (ELAN) | Axsome Therapeutics (AXSM) | |
|---|---|---|---|---|---|
|
Debt to Equity
|
1.16 | 0.00 | 0.00 | 0.58 | 0.00 |
|
Short term debt to equity ratio
|
0.00 | -0.22 | 0.00 | 0.01 | 0.85 |
|
Current Ratio
|
31.18 | 1.23 | 2.86 | 2.05 | 1.43 |
|
Quick Ratio
|
30.96 | 1.17 | 2.77 | 1.10 | 1.34 |
|
Interest Coverage
|
39.44 | -6.86 | -- | 0.36 | -37.09 |
Operating Efficiency Ratios
| Ligand Pharmaceuticals (LGND) | BridgeBio Pharma (BBIO) | Corcept Therapeutics (CORT) | Elanco Animal Health (ELAN) | Axsome Therapeutics (AXSM) | |
|---|---|---|---|---|---|
|
Debtors to sales (%)
|
24.07 | 36.78 | 9.26 | 22.95 | 35.73 |
|
Asset Turnover
|
0.18 | 0.39 | 0.84 | 0.33 | 0.65 |
|
Receivable days
|
70.50 | 52.44 | 28.27 | 70.73 | 104.82 |
|
Inventory Days
|
644.28 | 172.81 | 355.76 | 226.89 | 167.98 |
|
Payable days
|
234.84 | 296.14 | 785.55 | 45.50 | 529.03 |
|
Cash Conversion Cycle
|
479.94 | -70.89 | -401.52 | 252.12 | -256.23 |
*TTM (Trailing Twelve Months) data based on income statement of last 4 quarters and interim half yearly balance sheet.
loading...
loading...
New Process Alert 
Seems like you've uploaded a wrong QR code. Please upload the QR code downloaded from MF Central platform.
